• Species Reactivity

  Human

• Specificity

  Detects human Dermatopontin in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse Dermatopontin is observed.    
   

• Source

  Polyclonal Sheep IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human Dermatopontin    
  Gln19-Val201    
  Accession # AAH33736

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 μg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.2 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Dermatopontin

Dermatopontin, also known as TRAMP (tyrosine rich acidic matrix protein), is a widely expressed noncollagenous protein component of the extracellular matrix (1, 2). Mature human Dermatopontin shares 96%, 92%, and 92% amino acid sequence identity with bovine, mouse, and rat Dermatopontin, respectively. It is a 22 kDa molecule that is tyrosine sulfated but not glycosylated (3, 4). Dermatopontin contains three disulfide bonded loop structures that enclose conserved hexapeptide motifs (5). It accelerates collagen fibril formation in vitro, and Dermatopontin deficient mice exhibit altered collagen matrix deposition and organization (6 - 8). Dermatopontin is downregulated in fibrotic growths such as leiomyoma and scar tissue (9, 10). It binds both TGF-beta and the proteoglycan decorin, interactions that can increase the bioavailability of TGF-beta (11, 12). Dermatopontin promotes bone mineralization under the control of the vitamin D receptor and inhibits BMP-2 effects on osteoblast precursors (13, 14).

• References:

1. Okamoto, O. and S. Fujiwara (2006) Connect. Tissue Res. 47:177.

2. Superti-Furga, A. et al. (1993) Genomics 17:463.

3. Forbes, E.G. et al. (1994) FEBS Lett. 351:433.

4. Cronshaw, A.D. et al. (1993) Matrix 13:255.

5. Neame, P.J. et al. (1989) J. Biol. Chem. 264:5474.

6. MacBeath, J.R.E. et al. (1993) J. Biol. Chem. 268:19826.

7. Takeda, U. et al. (2002) J. Invest. Dermatol. 119:678.

8. Cooper, L.J. et al. (2006) Invest. Opthalmol. Vis. Sci. 47:3303.

9. Catherino, W.H. et al. (2004) Genes Chromosomes Cancer 40:204.

10. Kuroda, K. et al. (1999) J. Invest. Dermatol. 112:706.

11. Okamoto, O. et al. (1996) J. Biochem. 119:106.

12. Okamoto, O. et al. (1999) Biochem. J. 337:537.

13. Pochampally, R.R. et al. (2007) J. Bone Miner. Res. 22:1338.

14. Behnam, K. et al. (2006) Connect. Tissue Res. 47:271.

• Entrez Gene IDs:

  1805 (Human); 56429 (Mouse); 289178 (Rat)

• Alternate Names:

  Dermatopontin; DPT; Eq1; TRAMP; Tyrosine-rich acidic matrix protein